Matrix Dividend Income Strategy on Abbott Laboratories
Thesis
Matrix initiated a partial position in Abbott after a sharp pullback from its 52-week high. The fund likes Abbott's diversified healthcare businesses, recurring revenues, strong balance sheet and record of 54 years of dividend increases. At less than 16 times estimated 2026 earnings, the shares were trading at a substantial discount to both the market and Abbott's own valuation history while offering a 2.8% dividend yield at purchase.
“We believe that the company is an attractive investment for the portfolio because of its recurring revenues, strong balance sheet, 54 years of dividend increases”